Meenhard Herlyn

Molecular Biology · 2002–2018

A researcher in the Science corpus: 14 papers; trusts 6 researchers and is trusted by 1 researcher here, as inferred from the citation graph.

Subfields

• Molecular Biology — 133 citations into it; #16,036 of 17,773 by trust here, #1,986 by citations
• Oncology — 101 citations into it
• Cancer Research — 39 citations into it; #1,499 of 1,780 by trust here, #489 by citations
• Pulmonary and Respiratory Medicine — 19 citations into it
• Cell Biology — 14 citations into it
• Immunology and Allergy — 11 citations into it; #172 of 206 by trust here, #181 by citations

Whom Meenhard Herlyn trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. R. Hynes

Who trusts Meenhard Herlyn overall

1. Wen-Sheng Wu

Papers from Meenhard Herlyn's perspective

Ordered by how strongly the researchers Meenhard Herlyn trusts endorse each paper. Same corpus, a different order for every researcher.

1. The epithelial-mesenchymal transition generates cells with properties of stem cells. (Cell)
2. A molecular signature of metastasis in primary solid tumors (Nature Genetics)
3. Efficient tumor formation by single human melanoma cells (Nature)
4. Identification of selective inhibitors of cancer stem cells by high-throughput screening (Cell)
5. Development of matrix metalloproteinase inhibitors in cancer therapy. (Journal of the National Cancer Institute)
6. Involvement of chemokine receptors in breast cancer metastasis (Nature)
7. Functions of cell surface heparan sulfate proteoglycans.
8. Molecular portraits of human breast tumours (Nature)
9. Putting tumours in context (Nature Reviews. Cancer)
10. New functions for the matrix metalloproteinases in cancer progression (Nature Reviews. Cancer)

Their papers

• Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions (2005) — 2,107 citations
• A promoter-level mammalian expression atlas (2014) — 1,941 citations
• Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance (2017) — 1,120 citations
• A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth (2010) — 1,207 citations
• Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity (2008) — 1,352 citations
• A tumorigenic subpopulation with stem cell properties in melanomas. (2005) — 1,338 citations
• Exosomal PD-L1 Contributes to Immunosuppression and is Associated with anti-PD-1 Response (2018) — 2,430 citations
• Axis of evil: molecular mechanisms of cancer metastasis (2003) — 618 citations
• Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma (2018) — 622 citations
• A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade (2018) — 692 citations
• Overcoming intrinsic multi-drug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1Bhigh cells (2013) — 625 citations
• Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by co-targeting MEK and IGF-1R/PI3K (2010) — 1,289 citations
• High-throughput oncogene mutation profiling in human cancer (2007) — 1,054 citations
• BRAF and RAS mutations in human lung cancer and melanoma. (2002) — 1,126 citations